Background. Previous studies in different clinical settings have established heart rate variability (HRV) as a significant independent risk factor for higher mortality and cardiac death. The aim of this study was to examine the effect of chronic haemodialysis therapy on time-and frequencydomain parameters of HRV in diabetic and non-diabetic patients with chronic kidney disease (CKD). Methods. We studied 25 patients with stage 4 CKD and type 2 diabetes mellitus (CKD4+DM), 25 patients with stage 4 CKD without diabetes (CKD4), 25 patients with type 2 diabetes mellitus (DM) and 25 healthy subjects (HS). The study was performed in two phases. In the first phase, a 24-h Holter electrocardiographic (ECG) monitoring was performed in all subjects. The patients with stage 4 CKD were followed up until they progressed to stage 5, and in the second phase of the study, they underwent a 24-h Holter ECG monitoring after completion of 3months of conventional haemodialysis treatment. Results. In the first phase of the study, a reduction in cardiac sympathetic activity in CKD4 patients (significantly lower SDNN, SDANN/5 min, SD and VLF vs. HS) and worse autonomic function in CKD4+DM patients (significantly lower SDNN, SDANN/5 min, SD, VLF and LF/HF) vs. HS, DM and CKD4 was observed. After 3 months of dialysis therapy, the patients with CKD+DM showed a significant improvement only in the time-domain parameter SDANN/5 min, while the time-domain parameters SDNN, SDANN/5 min and SD were improved in CKD patients without diabetes. Frequency-domain parameters of HRV remained unchanged in both groups. Conclusions. CKD is associated with worse cardiac autonomic function. Haemodialysis therapy for 3 months improves some indices of HRV, and this effect is more pronounced in non-diabetic subjects. Our findings suggest that the improvement of HRV after the initiation of chronic dialysis therapy can ameliorate clinical outcomes and survival in patients with end-stage renal disease.
Introduction
In recent years, non-invasive techniques based on the electrocardiogram (ECG) have been used as markers of autonomic modulation of the heart; these include heart rate variability (HRV), baroreflex sensitivity (BRS), QT interval and heart rate turbulence (HRT) [1] . Among these techniques, analysis of HRV has emerged as a simple, non-invasive method to evaluate the sympatho-vagal balance at the sinoatrial level. It expresses the total amount of variations of both instantaneous HR and RR intervals (intervals between QRS complexes of normal sinus depolarizations) [2] . HRV has been used in different clinical settings including diabetes [3] , arterial hypertension [4] , coronary artery disease [5] , sudden cardiac death [6, 7] , chronic heart failure [8] and chronic kidney disease [9] , and for the screening of patients with obstructive sleep apnoea [10] . Reduced HRV has been established as a significant independent risk factor for higher mortality and cardiac death in cardiovascular disease and healthy populations [11, 12] . The Framingham Study has also reported that low HRV in healthy subjects is a risk factor for cardiac events [13] . Studies of HRV in end-stage renal disease (ESRD) patients have shown a decrement of HRV predictive of survival [14] [15] [16] . The study by Vita et al. [17] supports the use of power spectral analysis as a tool to detect autonomic dysfunction in uraemic patients, and the study by Hathaway et al. [18] supports the specificity of this method in uraemic diabetic patients.
In clinical practice, it is thought that both medical and non-medical strategies can be used to improve HRV. More aggressive treatment of coronary artery disease [19] , use of angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers (ARBs) and beta-blockers [20, 21] , and more frequent and/or nocturnal haemodialysis [22] can improve markers of HRV.
Interestingly, no literature data exist on the longitudinal effects of chronic dialysis therapy on HRV, focusing on end-stage renal disease patients with or without diabetes. The aim of this study was to examine the effect of chronic haemodialysis therapy (three times weekly, 4-h duration treatments) for 3 months on time-and frequency-domain parameters of HRV in diabetic and non-diabetic patients with end-stage renal disease.
Materials and methods

Subjects
One hundred patients attending the outpatient clinics and renal units of the participating hospitals were included in the study. They were divided into the following groups: 25 patients with stage 4 chronic kidney disease and type 2 diabetes mellitus (CKD4+DM), 25 patients with stage 4 chronic kidney disease without diabetes (CKD4), 25 patients with type 2 diabetes mellitus (DM) and 25 healthy subjects (HS).
Inclusion criteria for all subjects were age <75 years and serum albumin concentration >3.5 g/dL; inclusion criterion for CKD patients required that they had stage 4 CKD [glomerular filtration rate (GFR) 15-29 mL/min/ 1.73 m 2 ]. All non-diabetic patients had normal glucose tolerance. Patients were excluded from the study if they suffered from severe congestive heart failure, severe respiratory failure, cardiac arrhythmias, thyroid disease, epilepsy or Parkinson disease, or if they were on treatment with medications known to affect the autonomic nervous system activity [23] . In addition, we excluded from the study participants who suffered from severe haemodialysis hypotension with cardiovascular collapse due to acute illness and those who had fractional urea clearance (Kt/V) <1.2 during the 3 months haemodialysis treatment phase of the study. Subjects who were examined prior to initiation of haemodialysis and subsequently developed severe haemodialysis hypotension with cardiovascular collapse due to acute illness (n = 1) or had fractional urea clearance (Kt/V) <1.2 (n = 10) were not included in the study.
A total of 180 patients were screened for the study; 25 patients were excluded because of arrhythmia, 26 patients because of the use of medications with effect on cardiac autonomic nervous system activity, 10 patients because of uncontrolled thyroid disease, 10 patients because of low urea clearance, 5 patients with severe congestive heart failure, 3 patients with severe respiratory failure and 1 patient because of cardiovascular collapse during the haemodialysis due to upper gastrointestinal tract bleeding.
Study protocol
The study was performed according to the guidelines of the Helsinki Declaration and was approved by the ethics committees of the participating hospitals. Written informed consent was obtained from all subjects.
The study was divided in two phases. In the first phase, a 24-h Holter electrocardiographic (ECG) monitoring was performed in all subjects. The patients with stage 4 CKD were followed up until they progressed to stage 5 (following time lasted between 1.5 months and 1.1 years). In the second phase of the study, they underwent a 24-h Holter ECG monitoring after completing 3months of conventional haemodialysis treatment (three times weekly, 4-h duration treatments with polysulphone membranes, dialysis filter surface area according to patient body surface area). Holter monitor recording was started 3 h before the midweek haemodialysis session.
Determination of HRV
Digital ECG Holter recorder Spider View (ELA Medical, France) with seven electrodes was used to record three-channel ECGs in all subjects.
HRV was analysed from the Holter monitor recordings using commercially available software (ELA Medical SyneScope version 3.00 analysis system). The sampling rate of the ECG signal in SyneScope is 200 Hz (5 ms resolution). The SyneScope system automatically edits all artefacts and ectopic beats, and obtains a regular signal by linear interpolation of the HR tachogram. The beat classification was verified and corrected appropriately by an experienced cardiologist blinded to clinical details. SyneScope calculates the recommended time-and frequency-domain parameters of HRV according to the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology [24] .
Time-domain parameters used were: mean RR, SDNN (standard deviation, i.e. the square root of the variance of all NN intervals), SDANN/5 min [the standard deviation of the mean (average) of the RR intervals, each mean being calculated over 5 min], root mean squared of successive differences (RMSSD: corresponds to the square root of the mean differences in successive RR intervals) and PNN50 (the percentage difference between two consecutive NN intervals over 50 ms). The values of all time-domain parameters are expressed in milliseconds.
SyneScope uses a non-parametric method (fast Fourier transform-FFT) to calculate the frequency-domain parameters of HRV. The results presented are spectral powers in different frequency bands. Frequency-domain parameters used were: total power (≤0.4 Hz), very low frequency (VLF) band (0.003-0.04 Hz), low frequency (LF) band (0.04-0.15 Hz), high frequency (HF) band (0.15-0.4 Hz) and LF/HF ratio. The measurement of total power, VLF, LF and HF power components is made in absolute value of power (square milliseconds).
Laboratory measurements
Blood samples in the fasting state were taken in all subjects in the first phase of the study. Serum glucose, sodium, potassium, calcium, phosphorus and HbA 1 c were measured on an Architect (ABBOTT) 16200 analyser. Plasma insulin was determined by Microparticle Enzyme Immunoassay kits (ABBOTT IMx Insulin assay) on an IMx ABBOTT analyser. High-sensitivity CRP was measured by nephelometry (BN PRO-SPEC, DADE-BEHRING). GFR was calculated with the MDRD equation [25] , and insulin resistance was estimated by the homeostasis model assessment equation (HOMA-IR) [26] . During the second phase of the study, haemodialysis adequacy was assessed by monthly Kt/V measurements using the Daugirdas formula [27] .
Statistical analysis
Analysis of the data was performed using SPSS 10.0 for Windows ® statistical package. Data are shown as mean ± SEM (standard error of mean) or as numbers (n). All variables were tested for normal distribution of the values. Analysis of variance (ANOVA) was used to compare differences in the studied parameters among the four groups. When a P-value <0.05 was found in ANOVA, the post hoc LSD test was used to look for differences between the study groups. Categorical variables were compared by the chisquare test. For each group of CKD patients, a paired t-test was performed to look for differences in HRV parameters before and after initiation of dialysis treatment. P-values <0.05 (two-tailed significance) were considered statistically significant.
Results
The study groups did not differ significantly in terms of age, gender and waist circumference. The results of the comparison of the demographic, clinical and laboratory characteristics among the study groups are shown in Table 1 .
Insulin resistance (HOMA-IR) was higher in CKD4+DM patients in comparison with CKD4 (P = 0.01), DM (P = 0.04) and HS (P < 0.0001) groups. HbA 1 c was higher in the CKD4+DM group compared to CKD (P < 0.0001) and HS (P < 0.0001) groups. High-sensitivity CRP (hs-CRP) was elevated in patients with CKD4+DM compared to patients with DM (P = 0.02) and healthy subjects (P = 0.003). 
HRV alterations in stage 4 CKD
Differences in time-and frequency-domain parameters of HRV between the study groups are shown in Tables 2  and 3 . Mean RR was lower in CKD4+DM patients in comparison with CKD4 (P = 0.02) and HS (P = 0.01) groups. CKD4+DM patients showed lower values of SDNN, SDANN/5 min and SD than CKD4 (P < 0.001), DM (P < 0.001) and HS (P < 0.001) groups. Total power was lower in CKD4+DM patients vs HS group (P = 0.007). VLF was lower in CKD4+DM patients in comparison with CKD4 (P < 0.001), DM (P = 0.004) and HS (P < 0.001) groups. LF was lower in CKD4+DM patients vs HS (P = 0.001). CKD4+DM patients showed lower LF/HF ratio when compared to CKD4 (P = 0.001), DM (P = 0.02) and HS (P = 0.008) groups. CKD4 patients without diabetes showed lower values of SDNN, SDANN/5 min, SD and VLF in comparison with HS (P < 0.001, P < 0.001, P < 0.001 and P = 0.002, respectively). There was no difference in time-and frequency-domain parameters of HRV between CKD4 patients without diabetes and DM patients without CKD.
RMSSD and PNN50 did not differ between groups. During progression from stage 4 to stage 5 of CKD, no major changes in the medications used for the management of hypertension or diabetes were made, with exception of the discontinuation of the diuretic medications. In addition, haemoglobin levels and arterial blood pressure did not change significantly in patients with CKD stage 4 and after progression to CKD stage 5 with 3 months treatment with haemodialysis. Moreover, no significant changes were observed in HbA1c, CRP, insulin and HOMA-IR 3 months after initiation of haemodialysis in comparison with CKD stage 4.
Effects of chronic haemodialysis treatment on HRV
The effect of conventional haemodialysis treatment on HRV parameters for 3 months in diabetic and non-diabetic CKD patients is demonstrated in Tables 4 and 5 . CKD+DM patients, after 3 months of dialysis therapy, showed an improvement only in time-domain parameter SDANN/5 min (P = 0.03). Time-domain parameters SDNN, SDANN/ 5 min and SD were improved in CKD patients without diabetes, after 3 months of dialysis therapy (P = 0.03, P = 0.01 and P = 0.03, respectively). In the same group, HR was higher (P = 0.02), and mean RR was lower (P = 0.02) after 3 months of dialysis. Frequency-domain parameters of HRV remained unchanged after 3 months of chronic haemodialysis treatment in both groups.
Discussion
Interestingly, no literature data exist on the longitudinal effects of chronic dialysis therapy on HRV, focusing in endstage renal disease patients with or without diabetes. A limited number of studies refer to the changes in HRV parameters during the haemodialysis session, with conflicting results [28] [29] [30] .
In accordance with previous studies [31, 32] , we showed that diabetic patients without CKD have significantly lower values of time-and frequency-domain parameters of HRV in comparison with the healthy subjects. Autonomic dysfunction is common in patients with ESRD [33, 34] , and previous studies found also a reduced HRV in this population [14, 17] . Thus, our findings confirm previous observations showing that both time-and frequency-domain HRV measures are substantially decreased in CKD stage 4 patients compared with the healthy individuals. The lack of difference in HRV parameters between CKD4 patients compared to diabetics without CKD suggests that chronic kidney disease and diabetes mellitus have an equivalent detrimental effect on cardiac autonomic activity.
A dramatic decrement of HRV in patients with coexisting diabetes and CKD was observed in our patients. It has been shown that ESRD diabetic patients undergoing chronic haemodialysis therapy have a greater cardiovascular mortality than non-diabetic haemodialysed ESRD patients [35] . The exact reason for this difference remains unclear. However, it has been demonstrated that cardiac autonomic neuropathy represents a major complication of diabetes and is associated with a marked increase in mortality and cardiac arrhythmias [3] . One could hypothesize that cardiac autonomic activity may be further impaired in diabetic ESRD patients due to co-existence of uraemia and diabetic neuropathy.
In our study, patients with stage 4 CKD and diabetes, after progression to stage 5 and initiation of chronic haemodialysis therapy, showed an improvement in the SDANN/5 min parameter, while frequency-domain parameters in this group remained unchanged. In addition, patients with stage 4 CKD but without diabetes, after progression to stage 5 and initiation of chronic haemodialysis therapy, showed an improvement in the SDNN, SDANN/5 min and SD parameters, which reflect mainly the sympathetic nervous system activity, while frequency-domain parameters remained unchanged.
In a small study, by Dursun et al. [36] , 20 end-stage renal disease patients (13 on haemodialysis, 7 on continuous ambulatory peritoneal dialysis-CAPD) were evaluated to assess the effect of dialysis on autonomic function. After 12 months of dialysis, a significant improvement was observed in time-domain analysis that was found in the CAPD group compared to the HD group. This study was limited by the small sample size and did not discriminate between patients with CKD with or without diabetes.
In a recent study by Oikawa et al. [37] , assessing the prognostic value of HRV in 383 chronic haemodialysis patients, SDNN parameter showed the strongest relation to all-cause and cardiovascular death (hazard ratios 0.988 and 0.984, respectively). In the same study, the incidence of all-cause and cardiovascular death was much greater in patients with a low SDNN (<75 ms), even after adjusting for the presence of diabetes (P < 0.0001). In our study, SDNN values in patients with CKD+DM after the initiation of dialysis increased significantly at the level of 75 ms. The improved HRV seen after 3 months of conventional haemodialysis may be due to the exclusion of patients with poor dialysis adequacy (Kt/V <1.2). Our findings for improvement of HRV after the initiation of chronic dialysis therapy support the hypothesis that effective haemodialysis can ameliorate the clinical outcomes and survival in patients with end-stage renal disease.
In a study by Laaksonen et al. [38] in nine haemodialysis patients, improvement in HRV parameters occurred only in patients with Kt/V >1.2, while progressive deterioration of autonomic neuropathy was associated with a Kt/V <0.87. Diabetic patients (n = 4) were noted to have a severely abnormal HRV at the beginning of the study that did not improve over 2.9 years of the study. This study was limited by small sample size. A study of Rubinger et al. [28] suggests that haemodynamic instability during haemodialysis is strongly associated with a decreased HRV, due to sympathetic impairment and changes in sympathovagal balance. Intradialytic hypotension is common in haemodialysis populations and is considered to be a manifestation of autonomic nervous system dysfunction, leading to insufficient sympathetic response to ultrafiltration-induced hypovolaemia [39] .
To our knowledge, there are no large prospective studies assessing the longitudinal effects of haemodialysis on HRV in diabetic and non-diabetic CKD patients, a fact that may be due to the difficulties in the long-term follow-up of this population. This is the first prospective study with a sufficient number of diabetic and non-diabetic CKD patients, and the enrolment phase lasted almost 4 years. A limitation of our study may be that the longitudinal effects of haemodialysis were assessed 3 months after initiation of dialysis, a time period which may be short. One could hypothesize that HRV measurements might ameliorate further with chronic dialysis therapy, but the degree and the duration of improvement remain unclear. In the future, more robust trials and data are needed to confirm the beneficial longitudinal effects of haemodialysis in HRV. Secondly, data on HRV are not available for patients with CKD stage 5 before initiation of haemodialysis; however, the progression from late stage 4 to stage 5 is associated with deterioration of GFR and of parameters affecting HRV. The fact that the initiation of chronic haemodialysis improves HRV parameters even in comparison with CKD stage 4 suggests that a larger improvement may be seen in comparison with CKD stage 5 before initiation of haemodialysis.
Conclusion
CKD is associated with worse cardiac autonomic nervous system activity assessed by HRV. Diabetes is associated with compromised HRV in both patients with and without CKD. Haemodialysis therapy for 3 months improves some parameters of the HRV, and this effect is more pronounced in non-diabetic patients. Our findings suggest that the improvement of HRV after the initiation of chronic dialysis therapy can ameliorate clinical outcomes and survival in patients with end-stage renal disease.
